Can a simple urine test predict who benefits from PH treatment?

NCT ID NCT07254338

Recruiting now Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at small molecules (metabolites) in the blood and urine of people with pulmonary hypertension caused by lung fibrosis. Researchers want to see how these metabolites change with treatment and whether they can tell who will respond well. The goal is to better understand how treatments work and to avoid giving ineffective therapies to fragile patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients will benefit from PH treatments, reducing side effects and improving outcomes.
What could go wrong: This is an early exploratory study with only 80 participants, focused on biomarkers rather than direct treatment effects. Results may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE PRECAPILLAR PULMONARY HYPERTENSION

Contacts and locations

Locations

Hôpital Cardiologique et Pneumologique Louis Pradel
RECRUITING

Bron, Rhone, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.